Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Posts $1M in Q1 Revenue

NEW YORK (GenomeWeb News) – Exact Sciences today reported first-quarter revenues of $1 million compared to $51,000 in the first quarter of 2008.

The primary driver of that growth was license fees of almost $1 million attributable to its recent alliance with Genzyme. The Marlborough, Mass.-based molecular diagnostics firm said that the intellectual property transaction with Genzyme generated $17.2 million in cash, which will be recognized as revenue over 20 quarters as a non-cash allocation.

Exact posted a net loss of $3.8 million, or $.13 per share, compared to a net loss of $2.5 million, or $.09 per share, for the first quarter of 2008.

The company's R&D expenses fell sharply to $108,000 from $859,000 year over year, and its SG&A spending increased to $4.8 million from $1.8 million.

Exact finished the quarter with $3.6 million in cash and cash equivalents, and an additional $17 million in marketable securities.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.